A Treg-Modulating IKZF2 (Helios) Glue Degrader for Cancer Immunotherapy

DKY709

oral IKZF2-selective molecular glue degrader Ph. I/Ib for adv. solid tumors opt. of pomalidomide analog Cell Chemical Biology, March 1, 2023 Novartis, Cambridge, MA

Drug Hunter Team

DKY709, oral IKZF2-selective molecular glue degrader, Ph. I/Ib for adv. solid tumors, opt. of pomalidomide analog, Cell Chemical Biology, March 1, 2023, NOVARTIS, CAMBRIDGE, MA

A Treg-Modulating IKZF2 (Helios) Glue Degrader for Cancer Immunotherapy

DKY709

Other molecules you may be interested in